# A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors

> **NCT07038005** · PHASE1 · RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SPGL008

## Key facts

- **NCT ID:** NCT07038005
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2026-09-22
- **Final completion:** 2027-06-08
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07038005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07038005, "A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07038005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*